GE HEALTHCARE TECHNOLOGIES INC.

NASDAQ: GEHC (GE HealthCare Technologies Inc.)

Last update: 17 hours ago

79.80

0.23 (0.29%)

Previous Close 79.57
Open 78.94
Volume 742,079
Avg. Volume (3M) 3,135,653
Market Cap 36,492,382,208
Price / Earnings (TTM) 18.39
Price / Earnings (Forward) 17.15
Price / Sales 1.88
Price / Book 4.37
52 Weeks Range
74.51 (-6%) — 94.80 (18%)
Earnings Date 30 Apr 2025 - 14 May 2025
TTM Dividend Yield 0.16%
Profit Margin 10.13%
Operating Margin (TTM) 16.66%
Diluted EPS (TTM) 4.34
Quarterly Revenue Growth (YOY) 2.20%
Quarterly Earnings Growth (YOY) 78.90%
Total Debt/Equity (MRQ) 108.37%
Current Ratio (MRQ) 1.04
Operating Cash Flow (TTM) 1.95 B
Levered Free Cash Flow (TTM) 1.86 B
Return on Assets (TTM) 5.77%
Return on Equity (TTM) 25.69%

Market Trend

Short Term Medium Term
Industry Health Information Services (US) Mixed Mixed
Health Information Services (Global) Mixed Mixed
Stock GE HealthCare Technologies Inc. Bullish Bullish

AIStockmoo Score

0.4
Analyst Consensus 5.0
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages -5.0
Technical Oscillators -0.5
Average 0.38

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
GEHC 36 B 0.16% 18.39 4.37
TEM 8 B - - 180.35
HQY 8 B - 81.07 3.69
WAY 7 B - - 2.35
RCM 6 B - - 2.14
PRVA 3 B - 215.18 4.35

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (54% of revenue), ultrasound (18%), patient care solutions (16%), and pharmaceutical diagnostics (12%). The company’s sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 44%, 26%, 14%, and 16% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (33% of revenue), pharmaceutical diagnostics (12%), and digital solutions (6%).

Sector Healthcare
Industry Health Information Services
Investment Style Mid Core
% Held by Insiders 0.20%
% Held by Institutions 88.35%
52 Weeks Range
74.51 (-6%) — 94.80 (18%)
Price Target Range
100.00 (25%) — 110.00 (37%)
High 110.00 (Citigroup, 37.85%) Buy
Median 103.00 (29.07%)
Low 100.00 (Goldman Sachs, 25.31%) Buy
Average 104.00 (30.33%)
Total 4 Buy
Avg. Price @ Call 89.39
Firm Date Target Price Call Price @ Call
Goldman Sachs 11 Mar 2025 100.00 (25.31%) Buy 85.59
Wells Fargo 14 Feb 2025 103.00 (29.07%) Buy 92.21
Citigroup 13 Feb 2025 110.00 (37.84%) Buy 93.48
Jefferies 08 Jan 2025 103.00 (29.07%) Buy 86.26

No data within this time range.

Date Type Details
02 Apr 2025 Announcement FDA Watch: The Quiet Gold Rush in AI-Powered Medical Devices
31 Mar 2025 Announcement GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan
28 Mar 2025 Announcement GE HealthCare unveils Revolution™ Vibe CT system with Unlimited One-Beat Cardiac imaging and AI Solutions
27 Mar 2025 Announcement ACC 2025: GE HealthCare announces the U.S. launch of pivotal innovations that will help transform the cardiology care pathway
27 Mar 2025 Announcement GE HealthCare announces cash dividend for first quarter of 2025
20 Mar 2025 Announcement GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts
18 Mar 2025 Announcement GE HealthCare and NVIDIA reimagine diagnostic imaging with autonomous X-ray and ultrasound solutions
17 Mar 2025 Announcement GE HealthCare expands invasive cardiology solutions portfolio with AltiX AI.i for elevated experience in catheterization lab and electrophysiology procedures
04 Mar 2025 Announcement GE HealthCare Advances Its Cloud Strategy by Unveiling the Genesis Portfolio to Improve Speed of Digital Innovation Adoption
27 Feb 2025 Announcement GE HealthCare names new president and CEO, China
26 Feb 2025 Announcement GE HealthCare unveils Freelium, a next-generation sealed magnet platform at ECR 2025 to support equitable and sustainable access to MR
25 Feb 2025 Announcement Patients in the US undergo first doses of GE HealthCare’s new PET radiotracer, Flyrcado (flurpiridaz F 18) injection
13 Feb 2025 Announcement GE HealthCare reports fourth quarter and full year 2024 financial results
10 Feb 2025 Announcement GE HealthCare management to present at upcoming investor conference
31 Jan 2025 Announcement GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand
29 Jan 2025 Announcement GE HealthCare named to 2025 Fortune World’s Most Admired Companies™ list
28 Jan 2025 Announcement GE HealthCare unveils enhanced Voluson Expert Series women’s health ultrasound systems with focus on early detection and exam efficiency
15 Jan 2025 Announcement University of California San Francisco and GE HealthCare Launch a Joint Research Program to Drive Innovations in Imaging, Brain Health and Precision Oncology
14 Jan 2025 Announcement Sutter Health and GE HealthCare enter strategic partnership to benefit patients, physicians and clinicians with advanced, AI-powered imaging
Show more
TTM Dividend Yield 0.16%
2Y Average Dividend Yield 0.13%
Payout Ratio 2.76%
Expected Next Dividend Payment Aug 2025
Ex Date Announcement Date Payment Date Details
25 Apr 2025 27 Mar 2025 15 May 2025 0.035 Cash
14 Jan 2025 21 Nov 2024 14 Feb 2025 0.035 Cash
18 Oct 2024 18 Sep 2024 15 Nov 2024 0.03 Cash
19 Jul 2024 26 Jun 2024 15 Aug 2024 0.03 Cash
18 Apr 2024 22 Mar 2024 15 May 2024 0.03 Cash
12 Jan 2024 08 Dec 2023 15 Feb 2024 0.03 Cash
19 Oct 2023 22 Sep 2023 15 Nov 2023 0.03 Cash
20 Jul 2023 23 Jun 2023 15 Aug 2023 0.03 Cash
22 May 2023 25 Apr 2023 15 Jun 2023 0.03 Cash

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 0.070 2 0.09
2024 0.120 4 0.15
2023 0.090 3 0.12

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria